Is OS Therapies profitable?

OS Therapies is not currently profitable: it reported a net loss of $35.3M over the trailing twelve months.

What is OS Therapies's earnings per share?

OS Therapies's diluted EPS over the trailing twelve months is $-1.08.

Where does OS Therapies's income statement data come from?

Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

OS Therapies OSTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Research and development	$7.35M-16.4%	$8.8M+134%	$3.76M+50.2%	$2.5M+90.9%	$1.31M+50.4%
General and administrative	$2.82M-11.7%	$3.19M+2.1%	$3.12M+33.6%	$2.34M-36.6%	$3.69M+76.1%
Compensation and benefits	$1.44M-10.5%	$1.6M+96.9%	$814.93K-10.0%	$905.18K-3.8%	$941.28K+1,303%
Professional fees	$15.13K+300%	$3.78K0.0%	$3.78K0.0%	$3.78K0.0%	$3.78K—
Depreciation and amortization	$124.94K0.0%	$124.94K0.0%	$124.94K+11.0%	$112.51K+16,089%	$695-50.0%
Operating income	-$10.17M+15.2%	-$11.99M-74.3%	-$6.88M-42.2%	-$4.84M+3.2%	-$5M-68.5%
Interest expense	$75.34K—	——	——	——	——
Interest income	$45-16.7%	$54-16.9%	$65+1.6%	$64-3.0%	$66—
Other income (expense), net	-$228.89K+84.5%	-$1.47M-2,266,163%	$65-100.0%	$302.11K-73.1%	$1.12M+4,625%
Income tax expense	50%0.0%	50%—	——	——	50%0.0%
Net income	-$10.4M+22.8%	-$13.46M-95.7%	-$6.88M-51.6%	-$4.54M-17.0%	-$3.88M-29.6%
Preferred stock dividends	——	——	——	$0—	$0—
Diluted earnings per share	-$0.27+34.1%	-$0.41-95.2%	-$0.21-10.5%	-$0.19-5.6%	-$0.18+71.9%
Basic earnings per share	-$0.27+34.1%	-$0.41-95.2%	-$0.21-10.5%	-$0.19-5.6%	-$0.18+71.9%
Weighted-average shares, diluted	38.7M+32.2%	29.3M-8.5%	32M+27.2%	25.1M+18.2%	21.2M+206%
Adjustment For Amortization	$124.24K—	——	——	——	$0+100%
Adjustments To Additional Paid In Capital Purchase Of Prepaid Common Stock	$1.02M—	——	——	——	——
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	$1.44M-10.5%	$1.6M+96.8%	$814.93K-10.0%	$905.18K-3.8%	$941.28K+1,303%
Pre-tax stock-based compensation cost	$1.44M-10.5%	$1.6M+96.8%	$814.93K-10.0%	$905.18K-3.8%	$941.28K+251%
Amortization Of Financing Costs And Discounts	$68.97K—	——	——	——	-$1.12M—
Stock options excluded as their inclusion would be anti-dilutive (in shares)	12.6M+22.2%	10.3M—	——	——	——
Bundger Under Agreement	——	——	——	——	——
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect	$647.72K+140%	-$1.61M-73.6%	-$925.39K-448%	-$168.99K+93.4%	-$2.56M-170%
Clawback Of Common Stock For Over Issuance	——	——	——	——	——
Commitment Shares Issued For Equity Line Of Credit	——	——	——	——	$568.24K—
Conversion Of Makewhole Liability To Common Stock	——	——	——	——	——
Gross Proceeds	——	$625K0.0%	$625K0.0%	$625K0.0%	$625K—
Increase Decrease In Accrued Interest Receivable Net	-$6.37K—	——	——	——	——
Accrued liabilities	$3.88M+281%	$1.02M—	——	——	-$202.28K-190%
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	-$37.08K—	——	——	-$270+99.7%	-$96.99K—
Increase (Decrease) in Prepaid Expense	-$63.08K+81.5%	-$340.13K+2.5%	-$348.75K—	——	——
Invested Purchaser	——	$25K0.0%	$25K0.0%	$25K0.0%	$25K—
Issuance Of Stock And Warrants For Services Or Claims	$289.2K—	$0-100%	$239.25K+2,293%	$10K-97.1%	$346.59K+5,445%
Lease Cost	$750+300%	$187.50.0%	$187.50.0%	$187.50.0%	$187.5—
Legal Fees	$308.81K—	——	——	——	——
Milestone Payments	$22.38M—	——	——	——	$22.38M+300%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$5.21M+145%	$2.12M-43.8%	$3.78M+52.2%	$2.48M+136%	$1.05M-82.6%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	——	——	——	-$292.79K-68.6%	-$173.64K—
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$4.56M-22.3%	-$3.73M+20.7%	-$4.71M-99.4%	-$2.36M+31.4%	-$3.44M-44.9%
Number of operating segments	1—	——	——	——	1+300%
Number of reportable segments	1+300%	0.30.0%	0.30.0%	0.30.0%	0.3—
Operating Lease Payments	$811—	——	——	——	——
Original Issue Discount	——	10%—	——	——	——
Other Noncash Expense	——	——	——	——	——
Other Nonoperating Expense	$153.59K-58.3%	$368.25K0.0%	$368.25K0.0%	$368.25K0.0%	$368.25K+2,774%
Outstanding Balance Fees	$0—	$0—	$0+100%	-$148.59K-200%	$148.59K—
Payments to Acquire Productive Assets	——	——	——	$316.42K+111%	$150K—
Percentage Of Royalties	——	——	——	——	——
Percentage Of Royalty Payments	1.5%0.0%	1.5%—	——	——	——
Dividend rate of preferred stock per annum (as a percent)	——	——	——	——	——
Prepaid Shares	——	1.4M0.0%	1.4M—	——	——
Maturities of convertible senior notes	$1.84M—	——	——	——	——
Proceeds from Issuance of Common Stock	——	——	$1.05M+163%	$400K—	——
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants	——	——	——	——	$1.05M-30.4%
Proceeds From Related Party Debt	——	$33.55K0.0%	$33.55K0.0%	$33.55K0.0%	$33.55K-39.8%
Proceeds From Royalties Received	——	——	——	——	——
Proceeds From Warrant Exercises	——	——	——	——	$722.22K—
Reimbursable Grant Amount	——	——	——	——	——
Rent Expense	$2.43K-50.1%	$4.88K—	$0-100%	$2.36K-25.0%	$3.15K+620%
Repayment Of Shareholder Loan	——	——	——	——	$23.64K—
Royalty Net Sales Pecentage	6%0.0%	6%—	——	——	6%0.0%
Royalty Reduction Percentage	3%0.0%	3%—	——	——	3%0.0%
Stock-based compensation	$1.44M-10.5%	$1.6M+96.9%	$814.93K-10.0%	$905.18K-3.8%	$941.28K+1,303%
Granted (in shares)	2.1M-47.5%	3.9M—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	463.8K—	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions	——	——	——	4.1%-0.5%	4.6%+0.2%
Options canceled (in dollars per share)	$1.86—	——	——	——	——
Granted (in shares)	$1.47-18.3%	$1.80—	——	——	——
Shares Issued For Services	——	——	——	——	——
Preferred stock issuance	——	——	——	——	$263.25K—
Stock Issued During Period Shares Preferred Stock Seperable Units	1.5M—	——	——	——	——
Stock Issued During Period Shares To Investment Advisor	——	——	——	——	——
Stock Issued During Period Value Commitment Shares Issued For Equity Line Of Credit	——	——	——	——	$568.24K—
Stock Issued During Period Value Common Stock Issued For Services	——	$1.15M0.0%	$1.15M0.0%	$1.15M0.0%	$1.15M—
Stock Issued During Period Value Conversion Of Warrants To Common Stock	$2.35M—	——	$2.73M+10.0%	$2.48M—	——
Stock Issued During Period Value Issued For Services	$289.2K—	——	$239.25K+2,293%	$10K-99.3%	$1.45M+23,057%
Stock Issued During Period Value Sale Of Common Stock To Investors	——	$132.54K0.0%	$132.54K0.0%	$132.54K0.0%	$132.54K—
Stock Issued During Period Valueof Common Stockfor Patent License	——	$1.6M0.0%	$1.6M0.0%	$1.6M0.0%	$1.6M—
Stockholders Equity Note Warrant Exercise Inducement Expense	$949.37K—	——	——	——	——
Total Equity Value	——	——	——	$6.4M—	——
Warrant Exercise Price Decrease	$1.40—	——	——	——	——
Warrants Exercised And Proceeds Received Shares Pending Issuance	$567.4K+43.7%	$394.97K0.0%	$394.97K0.0%	$394.97K0.0%	$394.97K—
Warrants Issued In Connection With Convertible Bridge Notes	$567.4K—	——	——	——	——
Weighted Average Number Of Shares Issued Basic	$4.77M+300%	$1.19M0.0%	$1.19M0.0%	$1.19M0.0%	$1.19M—
EBIT	-$10.17M+15.2%	-$11.99M-74.3%	-$6.88M-42.2%	-$4.84M+3.2%	-$5M-68.5%
EBITDA	-$10.04M+15.3%	-$11.86M-75.6%	-$6.75M-42.9%	-$4.73M+5.5%	-$5M-68.6%
EBITDA	-$10.04M+15.3%	-$11.86M-75.6%	-$6.75M-42.9%	-$4.73M+5.5%	-$5M-68.6%
EBIT	-$10.17M+15.2%	-$11.99M-74.3%	-$6.88M-42.2%	-$4.84M+3.2%	-$5M-68.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is OS Therapies profitable?: OS Therapies is not currently profitable: it reported a net loss of $35.3M over the trailing twelve months.
What is OS Therapies's earnings per share?: OS Therapies's diluted EPS over the trailing twelve months is $-1.08.
Where does OS Therapies's income statement data come from?: Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.